<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00551642</url>
  </required_header>
  <id_info>
    <org_study_id>INOT27</org_study_id>
    <secondary_id>2004-002312-29</secondary_id>
    <nct_id>NCT00551642</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy Study of Nitric Oxide for Inhalation on Chronic Lung Disease in Premature Babies</brief_title>
  <official_title>The Effects of Nitric Oxide for Inhalation on the Development of Chronic Lung Disease in Pre-term Infants</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mallinckrodt</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mallinckrodt</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the safety and efficacy of inhaled nitric oxide to&#xD;
      reduce the risk of chronic lung disease in pre-term infants with respiratory distress, and to&#xD;
      assess the long-term effects of the therapy on the development of these children over 7 years&#xD;
      of clinical follow-up.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Although the effects of inhaled Nitric Oxide on pulmonary vascular tone are well-described&#xD;
      and relevant to term infants with persistent pulmonary hypertension, the pathophysiology of&#xD;
      respiratory failure in preterm infants may be quite different. Chronic lung disease (CLD)&#xD;
      represents the final pathway of a heterogeneous group of pulmonary disorders of infancy that&#xD;
      usually start in the neonatal period. CLD most commonly occurs in preterm (&lt;30 weeks of&#xD;
      gestational age (GA) infants with birth weights less than 1,500 grams (g), and especially in&#xD;
      those very preterm (&lt;26 weeks GA) with birth weights less than 1,000 g, and who have been&#xD;
      treated for respiratory distress syndrome (RDS).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 29, 2005</start_date>
  <completion_date type="Actual">July 17, 2015</completion_date>
  <primary_completion_date type="Actual">March 16, 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Survival Without Bronchopulmonary Dysplasia (BPD) in Preterm Infants With Respiratory Distress</measure>
    <time_frame>21 days</time_frame>
    <description>Survival without BPD is defined as the number of preterm infants of 36 weeks gestational age who survived the treatment period without the need for supplemental oxygen</description>
  </primary_outcome>
  <other_outcome>
    <measure>Mortality at 7-year Follow-up</measure>
    <time_frame>at 7-year Follow-up</time_frame>
    <description>Number of participants who died between 2 years and the 7-year Follow-up Period</description>
  </other_outcome>
  <other_outcome>
    <measure>Strengths and Difficulties Questionnaire Results for Participants at 7-year Follow-up</measure>
    <time_frame>At 7-year Follow-up</time_frame>
    <description>The Strengths and Difficulties Questionnaire contained 25 questions that were used to create 5 scales (ranging from 10=most normal to 0=most abnormal) for emotional symptoms, conduct problems, hyperactivity, peer problems, and (10=most abnormal, 0=most normal) for prosocial.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">800</enrollment>
  <condition>Lung Disease</condition>
  <arm_group>
    <arm_group_label>Inhaled Nitric Oxide (INO)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>INO administered by nasal continuous positive airway pressure, nasal cannula or face mask at 5 parts per million (ppm) for between 7 and 21 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo gas administered by nasal continuous positive airway pressure, nasal cannula or face mask, for a maximum of 21 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nitric oxide</intervention_name>
    <description>Nitric Oxide vapour (gas) for inhalation (400 ppm)</description>
    <arm_group_label>Inhaled Nitric Oxide (INO)</arm_group_label>
    <other_name>INO max®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo gas for inhalation</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Inborn preterm infants 24+0 weeks-28+6 days weeks gestational age (defined by first&#xD;
             trimester ultrasound or if not available based on the last menstrual period) who&#xD;
             requires the use of surfactant within 24 hours of birth (either prophylactically, or&#xD;
             for signs of developing respiratory distress), or who requires the use of continuous&#xD;
             positive airway pressure (CPAP) (fraction of inspired oxygen concentration (FiO2) ≥&#xD;
             0.30 on a mean airway pressure ≥ 4cm water (H2O)) within 24 hours of birth in order to&#xD;
             maintain an oxygen saturation (SpO2) ≥ 85%.&#xD;
&#xD;
          -  Informed consent of the guardian.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Outborn infants.&#xD;
&#xD;
          -  Infants ≥ 29 weeks gestational age.&#xD;
&#xD;
          -  Infants requiring FiO2 &gt;0.5 to maintain SpO2 &gt;85%, on a sufficient mean airway&#xD;
             pressure (e.g., &gt; 8 cm H2O on controlled mechanical ventilation (CMV)) in order to&#xD;
             achieve adequate chest inflation (8-9 ribs on Chest X-ray) two hours after the proper&#xD;
             administration of exogenous surfactant.&#xD;
&#xD;
          -  Any suspected congenital heart disease other than patent ductus arteriosus or atrial&#xD;
             septal defect.&#xD;
&#xD;
          -  Any infant with severe bleeding or coagulation abnormalities at high-risk of&#xD;
             diathesis, e.g., platelet &lt;50,000 per millimeter cube (mm³), fibrinogen &lt;0.5 gram per&#xD;
             liter (g/L), other clotting factors &lt;10%.&#xD;
&#xD;
          -  Any infant in whom a decision has been made not to provide full treatment, e.g.,&#xD;
             chromosomal abnormalities, severe multiple abnormalities, severe birth asphyxia, etc.&#xD;
&#xD;
          -  Use of another investigational drug or device before or during the active study&#xD;
             period.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>26 Hours</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Team Leader</last_name>
    <role>Study Director</role>
    <affiliation>Mallinckrodt</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UCL St. LUC</name>
      <address>
        <city>Bruxelles</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique Notre Dame</name>
      <address>
        <city>Charleroi</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitair Ziekenhuis Antwerpen</name>
      <address>
        <city>Edegem</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique St. Vincent CHC</name>
      <address>
        <city>Rocourt</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oulun yliopsistollinen sairaala</name>
      <address>
        <city>Oulu</city>
        <zip>FI-90220</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Intercommunal de Creteil</name>
      <address>
        <city>Creteil</city>
        <zip>94000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Mere-Enfant</name>
      <address>
        <city>Nantes Cedex 1</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Robert Debre</name>
      <address>
        <city>Paris</city>
        <zip>75019</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Campus Charite Mitte</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Heidelberg</name>
      <address>
        <city>Heidelberg</city>
        <zip>69115</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Mannheim</name>
      <address>
        <city>Mannheim</city>
        <zip>68167</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Marburg</name>
      <address>
        <city>Marburg</city>
        <zip>35033</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Muenchen</name>
      <address>
        <city>Muenchen</city>
        <zip>81377</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaeklinikum Tuebingen</name>
      <address>
        <city>Tuebingen</city>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univeritaetsklinik Ulm</name>
      <address>
        <city>Ulm</city>
        <zip>89075</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Az. Osp. G. Salesi</name>
      <address>
        <city>Ancona</city>
        <zip>60123</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedali Riuniti</name>
      <address>
        <city>Bergamo</city>
        <zip>24128</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Policlinico S. Orsola</name>
      <address>
        <city>Bologna</city>
        <zip>40138</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Careggi</name>
      <address>
        <city>Firenze</city>
        <zip>50134</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Padova</name>
      <address>
        <city>Padova</city>
        <zip>35128</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Policlinico Gemelli</name>
      <address>
        <city>Roma</city>
        <zip>00168</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beatrix Children's Hospital, University Medical Center Groningen</name>
      <address>
        <city>Groningen</city>
        <zip>9713 GZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sophia Kinderziekenhuis</name>
      <address>
        <city>Rotterdam</city>
        <zip>3000 CB</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Cruces</name>
      <address>
        <city>Barakaldo</city>
        <zip>48903</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Vall d'Hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Gregorio Mar</name>
      <address>
        <city>Madrid</city>
        <zip>28007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hosspital Univeritario La Paz</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Canarias</name>
      <address>
        <city>Santa Cruz de Tenerife</city>
        <zip>38320</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen del Rocio</name>
      <address>
        <city>Sevilla</city>
        <zip>41013</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario La Fe</name>
      <address>
        <city>Valencia</city>
        <zip>46009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Astrid Lindgrens barnsjukjus, Karolinska Unviersritets sjukhuset-Solna</name>
      <address>
        <city>Stockholm</city>
        <zip>SE-171 76</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Akademiska Sjukhuset</name>
      <address>
        <city>Uppsala</city>
        <zip>SE-751 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Meedway Mariton Hospital</name>
      <address>
        <city>Gillingham</city>
        <zip>ME7 5NY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leicester Royal Infirmary</name>
      <address>
        <city>Leicester</city>
        <zip>LE1 5WW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kings College</name>
      <address>
        <city>London</city>
        <zip>SE5 9RS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Finland</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>October 30, 2007</study_first_submitted>
  <study_first_submitted_qc>October 30, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 31, 2007</study_first_posted>
  <results_first_submitted>September 3, 2010</results_first_submitted>
  <results_first_submitted_qc>September 30, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 18, 2010</results_first_posted>
  <last_update_submitted>February 4, 2021</last_update_submitted>
  <last_update_submitted_qc>February 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Preemie, Inhaled Nitric Oxide</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nitric Oxide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Discussion of statistical endpoints and analysis are included in manuscripts. Summary aggregate (basic) results (including adverse events information) and the study protocol are made available on clinicaltrials.gov (NCT00551642) when required by regulation. Individual de-identified patient data will not be disclosed. Requests for additional information should be directed to the company at medinfo@mnk.com.</ipd_description>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Thirty-five Medical Centers participated and enrolled a total of 800 participants (Intent to treat population).</recruitment_details>
      <pre_assignment_details>800 participants were enrolled at 35 medical centers around the world for the Treatment period, and 305 had data at the 7-year Follow-up period.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Inhaled Nitric Oxide (INO)</title>
          <description>INO administered by nasal continuous positive airway pressure, nasal cannula or face mask at 5 parts per million (ppm) for between 7 and 21 days during the Treatment period, but no intervention during the 7-year Follow-up</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Placebo gas administered by nasal continuous positive airway pressure, nasal cannula or face mask, for a maximum of 21 days during the Treatment period, but no intervention during the 7-year Follow-up</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Treatment Period</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="399"/>
                <participants group_id="P2" count="401"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Safety Population</title>
              <participants_list>
                <participants group_id="P1" count="395"/>
                <participants group_id="P2" count="397"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="338"/>
                <participants group_id="P2" count="338"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="61"/>
                <participants group_id="P2" count="63"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Protocol Deviation</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Delivery device failure</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="33"/>
                <participants group_id="P2" count="31"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Inclusion/Exclusion criteria</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>7-Year Follow-up</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="152"/>
                <participants group_id="P2" count="153"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="152"/>
                <participants group_id="P2" count="153"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Inhaled Nitric Oxide (INO)</title>
          <description>INO administered by nasal continuous positive airway pressure, nasal cannula or face mask at 5 parts per million (ppm) for between 7 and 21 days during the Treatment period, but no intervention during the 7-year Follow-up</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Placebo gas administered by nasal continuous positive airway pressure, nasal cannula or face mask, for a maximum of 21 days during the Treatment period, but no intervention during the 7-year Follow-up</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="399"/>
            <count group_id="B2" value="401"/>
            <count group_id="B3" value="800"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Preterm newborn infants (gestational age &lt; 37 wks)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="399"/>
                    <measurement group_id="B2" value="401"/>
                    <measurement group_id="B3" value="800"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="192"/>
                    <measurement group_id="B2" value="181"/>
                    <measurement group_id="B3" value="373"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="207"/>
                    <measurement group_id="B2" value="220"/>
                    <measurement group_id="B3" value="427"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Survival Without Bronchopulmonary Dysplasia (BPD) in Preterm Infants With Respiratory Distress</title>
        <description>Survival without BPD is defined as the number of preterm infants of 36 weeks gestational age who survived the treatment period without the need for supplemental oxygen</description>
        <time_frame>21 days</time_frame>
        <population>All participants with efficacy data</population>
        <group_list>
          <group group_id="O1">
            <title>Inhaled Nitric Oxide (INO)</title>
            <description>INO administered by nasal continuous positive airway pressure, nasal cannula or face mask at 5 parts per million (ppm) for between 7 and 21 days during the Treatment period, but no intervention during the 7-year Follow-up</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo gas administered by nasal continuous positive airway pressure, nasal cannula or face mask, for a maximum of 21 days during the Treatment period, but no intervention during the 7-year Follow-up</description>
          </group>
        </group_list>
        <measure>
          <title>Survival Without Bronchopulmonary Dysplasia (BPD) in Preterm Infants With Respiratory Distress</title>
          <description>Survival without BPD is defined as the number of preterm infants of 36 weeks gestational age who survived the treatment period without the need for supplemental oxygen</description>
          <population>All participants with efficacy data</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="395"/>
                <count group_id="O2" value="400"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="258"/>
                    <measurement group_id="O2" value="262"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.7340</p_value>
            <method>Wald Chi-square</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.05</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Mortality at 7-year Follow-up</title>
        <description>Number of participants who died between 2 years and the 7-year Follow-up Period</description>
        <time_frame>at 7-year Follow-up</time_frame>
        <population>Participants with 7-year follow-up data</population>
        <group_list>
          <group group_id="O1">
            <title>Inhaled Nitric Oxide (INO)</title>
            <description>INO administered by nasal continuous positive airway pressure, nasal cannula or face mask at 5 parts per million (ppm) for between 7 and 21 days during the Treatment period, but no intervention during the 7-year Follow-up</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo gas administered by nasal continuous positive airway pressure, nasal cannula or face mask, for a maximum of 21 days during the Treatment period, but no intervention during the 7-year Follow-up</description>
          </group>
        </group_list>
        <measure>
          <title>Mortality at 7-year Follow-up</title>
          <description>Number of participants who died between 2 years and the 7-year Follow-up Period</description>
          <population>Participants with 7-year follow-up data</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="152"/>
                <count group_id="O2" value="153"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Strengths and Difficulties Questionnaire Results for Participants at 7-year Follow-up</title>
        <description>The Strengths and Difficulties Questionnaire contained 25 questions that were used to create 5 scales (ranging from 10=most normal to 0=most abnormal) for emotional symptoms, conduct problems, hyperactivity, peer problems, and (10=most abnormal, 0=most normal) for prosocial.</description>
        <time_frame>At 7-year Follow-up</time_frame>
        <population>Participants with Questionnaire Results at the 7-year follow-up</population>
        <group_list>
          <group group_id="O1">
            <title>Inhaled Nitric Oxide (INO)</title>
            <description>INO administered by nasal continuous positive airway pressure, nasal cannula or face mask at 5 parts per million (ppm) for between 7 and 21 days during the Treatment period, but no intervention during the 7-year Follow-up</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo gas administered by nasal continuous positive airway pressure, nasal cannula or face mask, for a maximum of 21 days during the Treatment period, but no intervention during the 7-year Follow-up</description>
          </group>
        </group_list>
        <measure>
          <title>Strengths and Difficulties Questionnaire Results for Participants at 7-year Follow-up</title>
          <description>The Strengths and Difficulties Questionnaire contained 25 questions that were used to create 5 scales (ranging from 10=most normal to 0=most abnormal) for emotional symptoms, conduct problems, hyperactivity, peer problems, and (10=most abnormal, 0=most normal) for prosocial.</description>
          <population>Participants with Questionnaire Results at the 7-year follow-up</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="147"/>
                <count group_id="O2" value="147"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Emotional (0=most normal, 10=most abnormal)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.9" spread="1.79"/>
                    <measurement group_id="O2" value="2.1" spread="1.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Conduct (0=most normal, 10=most abnormal)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.4" spread="1.55"/>
                    <measurement group_id="O2" value="1.4" spread="1.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hyperactivity (0=most normal, 10=most abnormal)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.8" spread="2.64"/>
                    <measurement group_id="O2" value="3.4" spread="2.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Peer problems (0=most normal, 10=most abnormal)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.2" spread="1.41"/>
                    <measurement group_id="O2" value="1.5" spread="1.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Prosocial (10=most abnormal, 0=most normal)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.6" spread="1.73"/>
                    <measurement group_id="O2" value="8.4" spread="1.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events (AEs), including clinically significant changes in vital signs, oxygen saturation, and laboratory values, were collected in the safety population for a maximum of 21 days (not during follow-up). All serious AEs are listed, and non-serious treatment-emergent adverse events (TEAEs) are listed if 5% or more participants in any arm experienced any form of that preferred term within 21 days. Survival was counted through the 7-year follow-up, and included under All-cause Mortality.</time_frame>
      <desc>In a previous submission of this record, &quot;Survival&quot;, &quot;Vital Signs&quot;, &quot;Arterial Oxygen Saturation by Pulse Oximetry&quot;, &quot;Adverse Events&quot; and &quot;Methemoglobin Level&quot; were incorrectly included as Outcome Measures, but have been deleted from the current version, because clinically significant changes in these parameters were counted under adverse events and/or all-cause mortality presented in this adverse events module.</desc>
      <group_list>
        <group group_id="E1">
          <title>Inhaled Nitric Oxide (INO)</title>
          <description>INO administered by nasal continuous positive airway pressure, nasal cannula or face mask at 5 parts per million (ppm) for between 7 and 21 days during the Treatment period, but no intervention during the 7-year Follow-up</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Placebo gas administered by nasal continuous positive airway pressure (nasal cannula or face mask) for a maximum of 21 days during the Treatment period, but no intervention during the 7-year Follow-up</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 10.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="56" subjects_at_risk="395"/>
                <counts group_id="E2" subjects_affected="48" subjects_at_risk="397"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="170" subjects_at_risk="395"/>
                <counts group_id="E2" subjects_affected="177" subjects_at_risk="397"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Coagulopathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="395"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="397"/>
              </event>
              <event>
                <sub_title>Disseminated intravascular coagulation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="395"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="397"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="395"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="397"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Arrhythmia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="395"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="397"/>
              </event>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="395"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="397"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="395"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="397"/>
              </event>
              <event>
                <sub_title>Cardiac tamponade</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="395"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="397"/>
              </event>
              <event>
                <sub_title>Cardio-respiratory arrest neonatal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="395"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="397"/>
              </event>
              <event>
                <sub_title>Cardiomyopathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="395"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="397"/>
              </event>
              <event>
                <sub_title>Cardiopulmonary failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="395"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="397"/>
              </event>
              <event>
                <sub_title>Intracardiac thrombus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="395"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="397"/>
              </event>
              <event>
                <sub_title>Supraventricular tachycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="395"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="397"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Coarctation of the aorta</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="395"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="397"/>
              </event>
              <event>
                <sub_title>Patent ductus arteriosus</sub_title>
                <counts group_id="E1" events="62" subjects_affected="62" subjects_at_risk="395"/>
                <counts group_id="E2" events="54" subjects_affected="54" subjects_at_risk="397"/>
              </event>
              <event>
                <sub_title>Persistent foetal circulation</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="395"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="397"/>
              </event>
              <event>
                <sub_title>Vitello-intestinal duct remnant</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="395"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="397"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hypopituitarism</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="395"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="397"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Retinopathy of prematurity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="395"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="397"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastric haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="395"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="397"/>
              </event>
              <event>
                <sub_title>Gastric perforation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="395"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="397"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="395"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="397"/>
              </event>
              <event>
                <sub_title>Gastrointestinal perforation</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="395"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="397"/>
              </event>
              <event>
                <sub_title>Ileus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="395"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="397"/>
              </event>
              <event>
                <sub_title>Intestinal obstruction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="395"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="397"/>
              </event>
              <event>
                <sub_title>Intestinal perforation</sub_title>
                <counts group_id="E1" events="17" subjects_affected="17" subjects_at_risk="395"/>
                <counts group_id="E2" events="14" subjects_affected="14" subjects_at_risk="397"/>
              </event>
              <event>
                <sub_title>Intussusception</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="395"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="397"/>
              </event>
              <event>
                <sub_title>Meconium ileus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="395"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="397"/>
              </event>
              <event>
                <sub_title>Meconium plug syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="395"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="397"/>
              </event>
              <event>
                <sub_title>Necrotising enterocolitis neonatal</sub_title>
                <counts group_id="E1" events="16" subjects_affected="16" subjects_at_risk="395"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="397"/>
              </event>
              <event>
                <sub_title>Oesophageal perforation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="395"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="397"/>
              </event>
              <event>
                <sub_title>Peritonitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="395"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="397"/>
              </event>
              <event>
                <sub_title>Pneumoperitoneum</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="395"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="397"/>
              </event>
              <event>
                <sub_title>Volvulus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="395"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="397"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Catheter related complication</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="395"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="397"/>
              </event>
              <event>
                <sub_title>Multi-organ failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="395"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="397"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Gallbladder perforation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="395"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="397"/>
              </event>
              <event>
                <sub_title>Jaundice</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="395"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="397"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Candidiasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="395"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="397"/>
              </event>
              <event>
                <sub_title>Catheter related infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="395"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="397"/>
              </event>
              <event>
                <sub_title>Endocarditis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="395"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="397"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="395"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="397"/>
              </event>
              <event>
                <sub_title>Postoperative wound infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="395"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="397"/>
              </event>
              <event>
                <sub_title>Pseudomonas infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="395"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="397"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="35" subjects_affected="34" subjects_at_risk="395"/>
                <counts group_id="E2" events="39" subjects_affected="35" subjects_at_risk="397"/>
              </event>
              <event>
                <sub_title>Staphylococcal bacteraemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="395"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="397"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Feeding tube complication</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="395"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="397"/>
              </event>
              <event>
                <sub_title>Subdural haematoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="395"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="397"/>
              </event>
              <event>
                <sub_title>Wound dehiscence</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="395"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="397"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Bacterial test positive</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="395"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="397"/>
              </event>
              <event>
                <sub_title>Blood cortisol decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="395"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="397"/>
              </event>
              <event>
                <sub_title>Blood growth hormone decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="395"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="397"/>
              </event>
              <event>
                <sub_title>Brain scan abnormal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="395"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="397"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Acidosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="395"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="397"/>
              </event>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="395"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="397"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="395"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="397"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Hepatic haemangioma rupture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="395"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="397"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Central nervous system lesion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="395"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="397"/>
              </event>
              <event>
                <sub_title>Cerebral ischaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="395"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="397"/>
              </event>
              <event>
                <sub_title>Cerebral ventricle dilatation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="395"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="397"/>
              </event>
              <event>
                <sub_title>Haemorrhage intracranial</sub_title>
                <counts group_id="E1" events="52" subjects_affected="50" subjects_at_risk="395"/>
                <counts group_id="E2" events="42" subjects_affected="42" subjects_at_risk="397"/>
              </event>
              <event>
                <sub_title>Hydrocephalus</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="395"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="397"/>
              </event>
              <event>
                <sub_title>Periventricular leukomalacia</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="395"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="397"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="395"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="397"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Aspiration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="395"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="397"/>
              </event>
              <event>
                <sub_title>Chylothorax</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="395"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="397"/>
              </event>
              <event>
                <sub_title>Emphysema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="395"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="397"/>
              </event>
              <event>
                <sub_title>Foreign body aspiration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="395"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="397"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="395"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="397"/>
              </event>
              <event>
                <sub_title>Laryngeal oedema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="395"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="397"/>
              </event>
              <event>
                <sub_title>Neonatal respiratory failure</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="395"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="397"/>
              </event>
              <event>
                <sub_title>Pneumomediastinum</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="395"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="397"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="395"/>
                <counts group_id="E2" events="15" subjects_affected="13" subjects_at_risk="397"/>
              </event>
              <event>
                <sub_title>Pulmonary haemorrhage</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="395"/>
                <counts group_id="E2" events="14" subjects_affected="14" subjects_at_risk="397"/>
              </event>
              <event>
                <sub_title>Pulmonary hypertension</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="395"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="397"/>
              </event>
              <event>
                <sub_title>Pulmonary interstitial emphysema syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="395"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="397"/>
              </event>
              <event>
                <sub_title>Respiratory acidosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="395"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="397"/>
              </event>
              <event>
                <sub_title>Respiratory arrest</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="395"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="397"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="395"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="397"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Chest tube insertion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="395"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="397"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="395"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="397"/>
              </event>
              <event>
                <sub_title>Haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="395"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="397"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="395"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="397"/>
              </event>
              <event>
                <sub_title>Infarction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="395"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="397"/>
              </event>
              <event>
                <sub_title>Vena cava thrombosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="395"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="397"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 10.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="358" subjects_at_risk="395"/>
                <counts group_id="E2" subjects_affected="334" subjects_at_risk="397"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="253" subjects_affected="189" subjects_at_risk="395"/>
                <counts group_id="E2" events="226" subjects_affected="168" subjects_at_risk="397"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" events="29" subjects_affected="29" subjects_at_risk="395"/>
                <counts group_id="E2" events="31" subjects_affected="28" subjects_at_risk="397"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Patent ductus arteriosus</sub_title>
                <counts group_id="E1" events="187" subjects_affected="183" subjects_at_risk="395"/>
                <counts group_id="E2" events="163" subjects_affected="158" subjects_at_risk="397"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperbilirubinaemia</sub_title>
                <counts group_id="E1" events="138" subjects_affected="122" subjects_at_risk="395"/>
                <counts group_id="E2" events="130" subjects_affected="120" subjects_at_risk="397"/>
              </event>
              <event>
                <sub_title>Jaundice</sub_title>
                <counts group_id="E1" events="107" subjects_affected="98" subjects_at_risk="395"/>
                <counts group_id="E2" events="97" subjects_affected="89" subjects_at_risk="397"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="75" subjects_affected="68" subjects_at_risk="395"/>
                <counts group_id="E2" events="66" subjects_affected="60" subjects_at_risk="397"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" events="100" subjects_affected="90" subjects_at_risk="395"/>
                <counts group_id="E2" events="75" subjects_affected="68" subjects_at_risk="397"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" events="22" subjects_affected="21" subjects_at_risk="395"/>
                <counts group_id="E2" events="21" subjects_affected="19" subjects_at_risk="397"/>
              </event>
              <event>
                <sub_title>Metabolic acidosis</sub_title>
                <counts group_id="E1" events="53" subjects_affected="49" subjects_at_risk="395"/>
                <counts group_id="E2" events="62" subjects_affected="52" subjects_at_risk="397"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Haemorrhage intracranial</sub_title>
                <counts group_id="E1" events="81" subjects_affected="73" subjects_at_risk="395"/>
                <counts group_id="E2" events="58" subjects_affected="55" subjects_at_risk="397"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Apnoea</sub_title>
                <counts group_id="E1" events="78" subjects_affected="73" subjects_at_risk="395"/>
                <counts group_id="E2" events="79" subjects_affected="78" subjects_at_risk="397"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="57" subjects_affected="55" subjects_at_risk="395"/>
                <counts group_id="E2" events="54" subjects_affected="50" subjects_at_risk="397"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Medical Information Call Center</name_or_title>
      <organization>Mallinckrodt</organization>
      <phone>800-556-3314</phone>
      <email>medinfo@mnk.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

